FDA Advisory Committee affirmed the drugs positive benefit/risk profile and unanimously voted in favor of the approval of FTY720 (fingolimod) as the treatment in relapsing remitting multiple sclerosis. FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing remitting MS.